en · de · es · fr · pt
cardarine-notes.peptides1126.com › Data › Detection, Regulation, And Quality Context — Quick Reference

Detection, Regulation, And Quality Context — Quick Reference

By Editorial Desk · published 2025-09-07 · last reviewed 2025-10-19 · Data

PPARδ agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-10-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Detection, Regulation, and Quality Context

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine as Investigational PPARδ Agonist

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Cardarine at a glance

PropertyValueNotes
WADA classificationS4 Hormone and Metabolic ModulatorsProhibited at all times in sport.
Drug approval statusNot approved in major jurisdictionsNo accepted therapeutic indication.
Common detection methodLC-MS/MSDetects parent compound and metabolites.
Typical test matrixUrine or bloodUrine is common in anti-doping testing.
Product labelingResearch chemical or supplementOften not independently verified.

Identity and Pharmacological Mechanism

Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Related pages on this site

Mechanism and Detection

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

Identity and Regulatory Status

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Supporting material

Blood accounts for 7% of the human body weight, with an average density around 1060 kg/m3, very close to pure water's density of 1000 kg/m3. The average adult has a blood volume of roughly 5 litres (11 US pt) or 1.3 gallons, which is composed of plasma and formed elements. The formed elements are the two types of blood cell or corpuscle – the red blood cells, (erythrocytes) and white blood cells (leukocytes) – and the cell fragments called platelets that are involved in clotting. By volume, the red blood cells constitute about 45% of whole blood, the plasma about 54.3%, and white cells about 0.7%.

In case of severe envenomation, death can occur as early as 30 minutes after being bitten, but average death time after a bite is around 3–6 hours and it is variable, depending on various factors such as the nature of the bite and the health state of the victim. Envenomation rate is very high: over 80% of bites inject venom. The mortality rate among untreated bite victims is nearly 100%.

Previously, UNAMA had reported that between 26 February and 16 March, at least 76 civilian were killed and 213 were injured in Afghanistan as result of armed clashes between Taliban forces and Pakistan armed forces. On the same day, Pakistani officials said that they had foiled an attempt by Taliban forces to attack a Pakistani border post in Khyber Pakhtunkhwa's Ghulam Khan Sector, killing 37 Taliban fighters and injuring 80 others. Furthermore, Pakistani officials stated that since the start of hostilities, 796 Afghan Taliban and TTP militants had been killed and more than 1,043 injured. They added that Pakistani forces had destroyed 286 check-posts, captured 44 others, destroyed 249 tanks, armored vehicles, and artillery guns, and targeted 81 locations across Afghanistan in air strikes. On 6 April, an Afghan media outlet, citing tribal elders and local residents, reported that Taliban forces had abandoned several border posts in Nuristan and Kunar following recent clashes with Pakistani forces. The abandoned positions were said to be located in the Bari Kot area of Nari district, as well as in parts of Bargi Matal and Kamdesh. According to the report, Taliban fighters who withdrew from the posts took shelter in village mosques. Some tribal elders from these area accuse the Taliban of failing to maintain security in the border areas and of spreading misinformation about their presence. They say that Taliban members travel by helicopter to district centres in order to create the impression that the group remains active in the region.

Sources: en.wikipedia.org

Supporting material

The US proposal included an end to Iran's nuclear program, limits on its missiles, reopening the Strait of Hormuz, restrictions on Iran's support for armed groups, and sanctions relief for Iran. The Iranians rejected the US proposal, with an anonymous official telling Press TV that "Iran will end the war when it decides to do so and when its own conditions are met". The Iranians issued a "5-point counter-proposal", including an end to US-Israeli attacks on Iran and pro-Iranian forces in Lebanon and Iraq, security guarantees to prevent future Israeli and US aggression, war reparations, and international recognition of Iranian sovereignty over the Strait of Hormuz. On 31 March, Pakistan delivered a "5 point initiative" for peace, calling for an immediate end to all hostilities and allowance of humanitarian aid into the region. Trump claimed on 1 April 2026 that Iran had just asked the US for a ceasefire and that the US would consider it once the Strait of Hormuz was "open, free, and clear. Until then, we are blasting Iran into oblivion ... back to the Stone Ages!". Iran's foreign ministry called the claim "false and baseless". The IRGC said the strait "will not be opened to the enemies of this nation through the ridiculous spectacle by the president of the US". On 8 April 2026, the United States and Iran agreed to a two-week ceasefire in the 2026 Iran war, mediated by Pakistan.

Calvatia gigantea, commonly known in English as the giant puffball, is a puffball mushroom found in meadows, fields, and deciduous forests in late summer and autumn. It is found in temperate areas throughout the world. It is edible when young.

=== Chemical properties === The attractive forces between polymer chains play a large part in determining the polymer's properties. Because polymer chains are so long, they have many such interchain interactions per molecule, amplifying the effect of these interactions on the polymer properties in comparison to attractions between conventional molecules. Different side groups on the polymer can lend the polymer to ionic bonding or hydrogen bonding between its own chains. These stronger forces typically result in higher tensile strength and higher crystalline melting points. The intermolecular forces in polymers can be affected by dipoles in the monomer units. Polymers containing amide or carbonyl groups can form hydrogen bonds between adjacent chains; the partially positively charged hydrogen atoms in N-H groups of one chain are strongly attracted to the partially negatively charged oxygen atoms in C=O groups on another. These strong hydrogen bonds, for example, result in the high tensile strength and melting point of polymers containing urethane or urea linkages. Polyesters have dipole-dipole bonding between the oxygen atoms in C=O groups and the hydrogen atoms in H-C groups. Dipole bonding is not as strong as hydrogen bonding, so a polyester's melting point and strength are lower than Kevlar's (Twaron), but polyesters have greater flexibility. Polymers with non-polar units such as polyethylene interact only through weak Van der Waals forces. As a result, they typically have lower melting temperatures than other polymers.

The team won the 1998 CARICOM Men's Basketball Championship, held at the Civic Centre in Belize City, and subsequently participated in the 1999 Centrobasquet Tournament in Havana. The national team finished seventh of eight teams after winning only 1 game despite playing close all the way. In a return engagement at the 2000 CARICOM championship in Barbados, Belize placed fourth. Shortly thereafter, Belize moved to the Central American region and won the Central American Games championship in 2001. The team has failed to duplicate this success finishing with a 2–4 record in the 2006 COCABA championship. The team finished second in the 2009 COCABA tournament in Cancun, Mexico where it went 3–0 in group play. Belize won its opening match in the Centrobasquet Tournament, 2010, defeating Trinidad and Tobago, but lost badly to Mexico in a rematch of the COCABA final. A tough win over Cuba set Belize in position to advance, but they fell to Puerto Rico in their final match and failed to qualify. Chess is played in Belize, with the country having national governing bodies for the sport: Belize Chess Federation and Belize National Youth Chess Foundation.

Sources: en.wikipedia.org

Frequently asked questions

How is cardarine detected in anti-doping tests?

Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.

Is cardarine legal?

Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.

What does a certificate of analysis show?

A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Network